Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Not Available]

    Molekuliarnaia Genetika, Mikrobiologiia I Virusologiia
    |December 19, 2018
    PubMed
    Summary
    This summary is machine-generated.

    Bacillus anthracis uses heme iron scavenged by hemophores and transporters during extracellular infection. This heme acquisition system differs from siderophore use during intracellular stages, offering potential new anthrax therapies.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    THE STRUCTURE OF THE INTESTINAL MICROBIOTA AND THE FREQUENCY OF DETECTION OF PATHOGENICITY GENES (STXI, STX2, BFP) IN ESCHERICHIA COLI WITH NORMAL ENZYMATIC ACTIVITY ISOLATED FROM CHILDREN DURING THE FIRST YEAR OF LIFE.

    Molekuliarnaia genetika, mikrobiologiia i virusologiia·2018
    Same journal

    DISTRIBUTION OF RNA-CONTAINING BEE VIRUSES IN HONEY BEE (APIS MELLIFERA) IN SEVERAL REGIONS OF RUSSIA.

    Molekuliarnaia genetika, mikrobiologiia i virusologiia·2018
    Same journal

    MOLECULAR EPIDEMIOLOGY OF TREPONEMA PALLIDUM IN BORDER REGION OF RUSSIAN FEDERATION (TUVA REPUBLIC).

    Molekuliarnaia genetika, mikrobiologiia i virusologiia·2018
    Same journal

    PENELOPE-LIKE RETROTRANSPOSONS IN THE GENOME OF ASIAN BLOOD FLUKE SCHISTOSOMA JAPONICUM (TREMATODA: SCHISTOSOMATIDAE).

    Molekuliarnaia genetika, mikrobiologiia i virusologiia·2018
    Same journal

    MOLECULAR-GENETIC PROPERTIES OF VIBRIO CHOLERAE EL TOR STRAINS CIRCULATING IN AFRICA.

    Molekuliarnaia genetika, mikrobiologiia i virusologiia·2018
    Same journal

    MOLECULAR TYPING OF SHIGELLA STRAINS.

    Molekuliarnaia genetika, mikrobiologiia i virusologiia·2018
    See all related articles

    Area of Science:

    • Microbiology
    • Bacterial Pathogenesis
    • Iron Metabolism

    Background:

    • Bacillus anthracis, the causative agent of anthrax, requires iron for survival and virulence.
    • Iron acquisition in bacteria is crucial for pathogenesis, with various strategies employed.
    • B. anthracis utilizes both siderophore-mediated and heme-acquisition systems.

    Purpose of the Study:

    • To elucidate the structure, genetic organization, and functions of the heme iron acquisition system in B. anthracis.
    • To understand the distinct roles of heme and siderophore iron acquisition during different stages of anthrax infection.
    • To identify potential therapeutic targets for novel anthrax treatments.

    Main Methods:

    • Analysis of the genetic organization of heme acquisition genes.

    Related Experiment Videos

  • Characterization of hemophore and transporter protein functions.
  • Investigation of iron acquisition strategies during in vitro and in vivo infection models.

    • Main Results:

    • B. anthracis employs a heme acquisition system involving hemophores and transporter proteins for extracellular iron scavenging from hemoglobin.
    • The heme acquisition system is predominantly active during the extracellular stage of anthrax infection.
    • Siderophore-mediated iron uptake is the primary mechanism during the intracellular stage of B. anthracis development.

    Conclusions:

    • The heme iron acquisition system represents a critical virulence factor for B. anthracis during extracellular infection.
    • Understanding this system provides insights into bacterial iron metabolism and pathogenesis.
    • Targeting the heme acquisition pathway could lead to the development of new anti-anthrax therapies.